Capricor Therapeutics (CAPR) financial statements
Capricor Therapeutics reported revenue of $0 in fiscal 2025, up 23.9% a year over 8 years.
Net income was -$105M.
Free cash flow was -$73M.
The diluted share count rose 2405% over the period (dilution).
Revenue and free cash flow
Fiscal years, $ billions.
Income statement
Fiscal years, from Capricor Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4M | $3M | $2M | $1M | $310,250 | $244,898 | $3M | $25M | $22M | $0 |
| Research and development | $16M | $11M | $12M | $5M | $8M | $14M | $22M | $36M | $50M | $84M |
| Selling, general and admin | $5M | $5M | $5M | $4M | $6M | $8M | $10M | $13M | $15M | $24M |
| Operating income | -$17M | -$13M | -$15M | -$8M | -$14M | -$21M | -$30M | -$24M | -$43M | -$108M |
| Interest expense | $344,665 | $398,807 | $0 | — | — | — | — | — | $0 | $3M |
| Pre-tax income | — | — | — | — | — | — | — | — | -$40M | -$105M |
| Income tax | — | — | — | — | — | — | — | — | $1,600 | $1,600 |
| Net income | -$19M | $2M | -$15M | -$8M | -$14M | -$20M | -$29M | -$22M | -$40M | -$105M |
| EPS (diluted) | -$10.10 | $0.90 | -$5.20 | -$2.06 | -$0.88 | -$0.87 | -$1.18 | -$0.83 | -$1.15 | -$2.26 |
| Diluted shares | 2M | 3M | 3M | 4M | 16M | 23M | 25M | 27M | 35M | 46M |
| Operating margin | -424.6% | -482.4% | -917.0% | -769.5% | -4412.6% | -8549.9% | -1163.9% | -95.6% | -191.1% | — |
| Net margin | -470.3% | 91.2% | -908.9% | -760.4% | -4401.9% | -8175.9% | -1137.4% | -88.5% | -181.7% | — |
Balance sheet
Fiscal years, from Capricor Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and short-term investments | $16M | $14M | $7M | $10M | $33M | $35M | $41M | $40M | $152M | $318M |
| Total current assets | $18M | $16M | $8M | $11M | $34M | $36M | $43M | $51M | $163M | $323M |
| Property, plant and equipment | $435,336 | $372,096 | $574,206 | $442,806 | $850,847 | $2M | $5M | $6M | $6M | $18M |
| Total assets | $19M | $16M | $9M | $11M | $35M | $41M | $50M | $59M | $170M | $356M |
| Total current liabilities | $5M | $2M | $1M | $897,992 | $3M | $4M | $24M | $31M | $21M | $36M |
| Total liabilities | $23M | $5M | $5M | $4M | $6M | $10M | $38M | $36M | $25M | $50M |
| Shareholders' equity | -$4M | $11M | $5M | $7M | $28M | $31M | $12M | $23M | $145M | $306M |
| Net debt | -$3M | -$6M | -$4M | -$4M | -$33M | -$35M | -$10M | -$15M | -$11M | -$288M |
Cash flow
Fiscal years, from Capricor Therapeutics's 10-K filings with the SEC.
| Fiscal year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$14M | -$14M | -$14M | -$7M | -$10M | -$17M | $5M | -$26M | -$40M | -$70M |
| Capital spending | $191,970 | $32,185 | $316,486 | $0 | $547,601 | $1M | $2M | $1M | $1M | $3M |
| Free cash flow | -$15M | -$14M | -$14M | -$7M | -$11M | -$18M | $3M | -$27M | -$41M | -$73M |
| Stock-based compensation | $2M | $2M | $2M | $700,984 | $2M | $3M | $4M | $7M | $10M | $17M |
| Share buybacks (net) | — | — | $0 | -$193 | $0 | — | — | — | — | — |
| Net borrowing | $5M | $500,000 | $0 | — | — | — | — | — | — | — |
| Free cash flow margin | -366.3% | -534.9% | -848.3% | -678.7% | -3417.4% | -7352.3% | 114.3% | -106.9% | -184.8% | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for CAPR.
Open CAPR in InvestinglyQuestions
What was Capricor Therapeutics's revenue in 2025?
$0 in fiscal 2025, from its 10-K filing.
How much free cash flow does Capricor Therapeutics generate?
-$73M in fiscal 2025 (operating cash flow minus capital spending).
From Capricor Therapeutics's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.